Ghrelin and growth hormone combination therapy - TheraSource
Latest Information Update: 04 Aug 2016
At a glance
- Originator TheraSource
- Class Growth hormones; Peptide hormones
- Mechanism of Action Ghrelin receptor agonists; Somatotropin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes - Sepsis
Highest Development Phases
- Preclinical Sepsis
Most Recent Events
- 04 Aug 2016 Ghrelin and growth hormone combination therapy - TheraSource is available for licensing as of 04 Aug 2016. http://therasourceinc.com/